Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 18/20 | 0.44 |
| ▸ | JAK1 | P23458 | 18/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4413039 | 0.94 | JAK2 (0.47) | JAK2JAK1GPR119DPP4 | |
| SCHEMBL3523465 | 0.92 | JAK2 (0.42) | JAK2JAK1GPR119 | |
| SCHEMBL4407208 | 0.92 | JAK2 (0.41) | JAK2JAK1 | |
| SCHEMBL3525497 | 0.89 | GPR119 (0.41) | JAK2JAK1GPR119DPP4 | |
| SCHEMBL14272848 | 0.89 | JAK2 (0.40) | JAK2JAK1 | |
| SCHEMBL4405768 | 0.89 | JAK2 (0.47) | JAK2JAK1 | |
| SCHEMBL5916161 | 0.87 | GPR119 (0.45) | JAK2JAK1GPR119 | |
| SCHEMBL16554255 | 0.87 | MEN1 (0.44) | JAK2JAK1 | |
| SCHEMBL3530835 | 0.86 | GPR119 (0.42) | JAK2JAK1GPR119 | |
| SCHEMBL3523742 | 0.85 | TP53 (0.46) | JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558577-B1 | SUBSTITUTED 4-PHENYL-PIPERIDIN-AMIDES AS TACHYKININ ANTAGONISTS AND SEROTONIN REPTAKE INHIBITORS | GLAXO GROUP LTD (GB) | 2009-12-30 | — | — | EP | disclosed |
| US-20060128752-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128752-A1 | Chemical compounds | HTR7, NPSR1, TACR2 | JAK2 1826/4885JAK1 3006/4885GPR119 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.